Adynamic bone revisited: Is there progress?

Peritoneal Dialysis International

Volumn 26, Issue 1, 2006, Pages 43-48

  Sanchez, Cheryl P ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; CALCIUM; GLUCOSE; INSULIN; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; VITAMIN D; VITAMIN D RECEPTOR; BIOLOGICAL MARKER;

ARTICLE; BONE DISEASE; BONE MINERALIZATION; BONE TURNOVER; CHRONIC KIDNEY FAILURE; DRUG TOLERABILITY; HEMODIALYSIS; HORMONE SYNTHESIS; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERPHOSPHATEMIA; INSULIN DEFICIENCY; LOW DRUG DOSE; NONHUMAN; OSTEOCLAST; OSTEOMALACIA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PARATHYROID HYPERPLASIA; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; BLOOD; DISEASE COURSE; NOTE; RENAL OSTEODYSTROPHY; RISK FACTOR;

BIOLOGICAL MARKERS; CALCIUM; DISEASE PROGRESSION; HUMANS; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; RENAL OSTEODYSTROPHY; RISK FACTORS; VITAMIN D;

EID: 33745489134     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080602600107     Document Type: Article

References (71)

1. Sherrard DJ, Baylink DJ, Wergedal JE, Maloney NA. Quantitative histological studies on the pathogenesis of uremic bone disease. J Clin Endocrinol Metab 1974; 39: 119-35.
2. Witmer G, Margolis A, Fontaine O, Fritsch J, Lenoir G, Brayer M, et al. Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure. Kidney Int 1976; 10:395-408.
3. 3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron 1989; 53:93-101.
4. Mathias R, Salusky IB, Harmon W, Paredes A, Emans J, Segre G, et al. Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital. J Am Soc Nephrol 1993; 3:1938-46.
5. Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994; 45:253-8.
6. Sherrard DJ. Aplastic bone: a non-disease of medical progress. Adv Ren Replace Ther 1995; 2:20-3.
7. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995; 26:836-44.
8. Bervoets AA, Spasovski GB, Behets GA, Dams G, Polenakovic MH, Zafirovska K, et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 2003; 41:997-1007.
9. Ziolkowska H, Paniczyk-Tomaszewska M, Debinski A, Polowiec Z, Sawizki A, Sieniawska M. Bone biopsy results and serum bone turnover parameters in uremic children. Acta Paediatr 2000; 89:666-71.
10. Pei Y, Hercz G, Greenwood C, Segre GV, Manuel A, Saiphoo C, et al. Renal osteodystrophy in diabetic patients. Kidney Int 1993; 44:159-64.
11. Andress D, Hercz G, Kopp J, Endres DB, Norris KC, Coburn JW, et al. Bone histomorphometry of renal osteodystrophy in diabetic patients. J Bone Miner Res 1987; 2:525-31.
12. Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolshy E. Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int 1990; 37:1522-7.
13. Jara A, Bover J, Felsenfeld AJ. Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. Kidney Int 1995; 47:1746-51.
14. Contiguglia S, Alfrey A, Miller N, Butkus D. Total-body magnesium excess in chronic renal failure. Lancet 1972; 1:1300-2.
15. Ng A, Hercz G, Kandel R, Grynpas MD. Association between fluoride, magnesium, aluminum and bone quality in renal osteodystrophy. Bone 2004; 34:216-24.
16. Moriniere P, Vinatier I, Westeel P, Cohemsolal M, Belbrik S, Abdulmassih Z, et al. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation. Nephrol Dial Transplant 1988; 3:651-6.
17. Morrissey J, Slatopolsky E. Effect of aluminum on parathyroid hormone secretion. Kidney Int Suppl 1986; 18:S41-4.
18. Goodman WG. Experimental aluminum-induced bone disease: studies in vivo. Kidney Int Suppl 1986; 18:S32-6.
19. Sherrard DJ. Aluminum and renal osteodystrophy. Semin Nephrol 1986; 6:5-11.
20. Avila-Diaz M, Matos M, Garcia-Lopez E, Prado MC, Castro-Vazquez F, Ventura MJ, et al. Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis. Perit Dial Int 2006; 26:78-84.
21. Mak RH, Turner C, Thompson T, Powell H, Haycock GB, Chantler C. Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide. Br Med J (Clin Res Ed) 1985; 291:623-7.
22. Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 2000; 57:282-92.
23. Tamanaha K, Mak R, Rigden S, Turner C, Start KM, Haycock GB, et al. Long-term suppression of hyperparathyroidism by phosphate binders in uremic children. Pediatr Nephrol 1987; 1:145-9.
24. Sanchez CP, Kuizon BD, Abdella PA, Juppner H, Salusky IB, Goodman WB. Impaired growth, delayed ossification, and reduced osteoclastic activity in the growth plate of calcium-supplemented rats with renal failure. Endocrinology 2000; 141:1536-44.
25. WAF1 and TGF-mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 2001; 60:2109-17.
26. Goodman WG, Goldin J, Kuizon B, Yoon C, Gales B, Sider D, et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-83.
27. Block GA. Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol 2000; 54:318-24.
28. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld V, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106:100-5.
29. Kurz P, Monier-Faugere M-C, Bognar B, Werner E, Roth P, Vlachojannis J, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46:855-61.
30. Bro S, Brandi L, Daugaard H, Olgaard K. Calcium concentration in the CAPD dialysate: what is optimal and is there a need to individualize? Perit Dial Int 1997; 17:554-9.
31. Weinreich T, Ritz E, Passlick-Deetjen J. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group. Perit Dial Int 1996; 16:260-8.
32. Kurz P, Tsobanelis T, Brunkhorst R, Roth P, Werner E, Schoeppe W, et al. Calcium kinetic studies in patients on CAPD: improvement of secondary hyperparathyroidism without concomitant improvement of calcium turnover. Perit Dial Int 1997; 17:59-65.
33. 3 on cartilage growth in neonatal mice. Metab Bone Dis Relat Res 1983; 4:337-45.
34. 3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35:1049-56.
35. Klaus G, Meinhold-Heerlein R, Milde P, Ritz E, Mehls O. Effect of vitamin D on growth cartilage cell proliferation in vitro. Pediatr Nephrol 1991; 5:461-6.
36. Goodman WG, Ramirez JA, Belin TR, Ritz E, Mehls O. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46:1160-6.
37. Salusky IB, Kuizon BD, Belin TR, Ramirez JA, Gales B, Segre GV, et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 1998; 54:907-14.
38. NKF: K/DCQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 46(Suppl 1):S1-121.
39. Slatopolsky E, Berkoben M, Kelber J, Brown A, Delmez J. Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism. Kidney Int Suppl 1992; 42: S43-9.
40. Coburn J, Maung H, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004; 43:877-90.
41. 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9:1427-32.
42. 2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001; 37:532-43.
43. Hofbauer LC, Heufelder AE. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. Eur J Endocrinol 1998; 139:152-4.
44. Coen G, Ballanti P, Balducci A, Calabria S, Fischer MS, Jankovic L, et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002; 17:233-8.
45. Avbersek-Luznik I, Balon BP, Rus I, Marc J. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant 2005; 20:566-70.
46. Avbersek-Luznik I, Malesic I, Rus I, Marc J. Increased levels of osteoprotegerin in hemodialysis patients. Clin Chem Lab Med 2002; 40:1019-23.
47. Brossard J-H, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996; 81:3923-9.
48. D'Amour P, Brossard J-H, Rousseau L, Roy L, Gao P, Cantor T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003; 49:2037-44.
49. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58:753-61.
50. Lehmann G, Stein G, Huller M, Schemer R, Ramakrishnan K, Goodman WG. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 2005; 68:1206-14.
51. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, et al. Similar predictive value of bone turnover using the first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 2003; 63:1801-8.
52. Bover J, Jara A, Trinidad P, Rodriguez M, Martin-Malo A, Felsenfeld AJ. The calcemic response to PTH in the rat: effect of elevated PTH levels and uremia. Kidney Int 1994; 46:310-17.
53. Galceran T, Martin KJ, Morrissey JJ, Slatopolsky E. Role of 1,25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormone. Kidney Int 1987; 32:801-7.
54. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75:145-50.
55. NKF.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 3):S1-S201.
56. Picton M, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 2000; 58:1440-9.
57. Coen G, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V, et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998; 13:2294-302.
58. Chu P, Chao T-Y, Lin Y-F, Janckila AJ, Yam LT. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 2003; 41:1052-9.
59. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36:1115-21.
60. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 22:287-93.
61. Ubara Y, Tagami T, Nakanishi S, Sawa N, Hoshino J, Suwabe T, et al. Significance of minimodeling in dialysis patients with adynamic bone disease. Kidney Int 2005; 68:833-9.
62. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24:1161-70.
63. Avram MM, Mittman N, Myint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38:1351-7.
64. Kuizon BD, Goodman WG, Juppner H, Boechat I, Nelson P, Gales B, et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 1998; 53:205-11.
65. Salem M, Sanchez C, Kuizon B, Gales B, Goodman WG, Salusky IB. Renal bone diseases in children with chronic renal failure [Abstract]. J Am Soc Nephrol 1998; 9:549A.
66. Waller SC, Ridout D, Cantor T, Rees L. Parathyroid hormone and growth in children with chronic renal failure. Kidney Int 2005; 67:2338-45.
67. Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ, et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005; 16: 2501-8.
68. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999; 55:299-307.
69. Behets GJ, Verberckmoes SC, Oste L, Bervoets AR, Salome M, Cox AG, et al. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 2005; 67: 1830-6.
70. Lacour B, Lucas A, Auchère D, Ruellan N, de Serre Patey NM, Drueke TB, et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005; 67:1062-9.
71. Weinrich T, Passlick-Deetjen J, Ritz E. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. Am J Kidney Dis 1995; 25:452-60.